Hydrolytic activity of alpha-galactosidases against deoxy derivatives of p-nitrophenyl alpha-D-galactopyranoside.

The four possible monodeoxy derivatives of p-nitrophenyl (PNP) alpha-D-galactopyranoside were synthesized, and hydrolytic activities of the alpha-galactosidase of green coffee bean, Mortierella vinacea and Aspergillus niger against them were elucidated. The 2- and 6-deoxy substrates were hydrolyzed by the enzymes from green coffee bean and M. vinacea, while they scarcely acted on the 3- and 4-deoxy compounds. On the other hand, A. niger alpha-galactosidase hydrolyzed only the 2-deoxy compound in these deoxy substrates, and the activity was very high. These results indicate that the presence of two hydroxyl groups (OH-3 and -4) is essential for the compounds to act as substrates for the enzymes of green coffee bean and M. vinacea, while the three hydroxyl groups (OH-3, -4, and -6) are necessary for the activity of the A. niger enzyme. The kinetic parameters (K(m) and Vmax) of the enzymes for the hydrolysis of PNP alpha-D-galactopyranoside and its deoxy derivatives were obtained from kinetic studies.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.

Recently we reported the identification of a series of 8-[[3-(N-acylglycyl-N-methylamino)-2, 6-dichlorobenzyl]oxy]-3-halo-2-methylimidazo[1,2-a]pyridines as the first orally active non-peptide bradykinin (BK) B2 receptor antagonists (1-3). These compounds inhibited the specific binding of [3H]BK to guinea pig ileum membrane preparations expressing B2 receptors with nanomolar IC50's and also displayed in vivo functional antagonistic activities against BK-induced bronchoconstriction in guinea pigs at 1 mg/kg by oral administration. However, it was found that their affinities for the B2 receptors in human A-431 cells (human epidermoid carcinoma) were much lower. Intensive modifications of the terminal substituents at the glycine moiety elucidated the structure-activity relationships (SAR) for human B2 receptors, leading to an extended basic framework which incorporated a novel key pharmacophore. Thus, we overcame the species difference and identified the first clinical candidate 18c (FR167344) with IC50's of 0.66 and 1.4 nM for guinea pig ileum and human A-431 cells, respectively. This compound displayed in vivo functional antagonistic activity against BK-induced bronchoconstriction in guinea pigs with an ED50 value of 0.17 mg/kg by oral administration. This novel non-peptide B2 antagonist is extremely potent both in vitro and in vivo by oral administration and is expected to be the first member of a new class of drug for the treatment of various inflammatory diseases.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2, 6-dichlorobenzyl]oxy]-3-halo-2-methylimidazo[1,2-a]pyridine skeleton, leading to identification of the first clinical candidate 4a (FR167344). With this potent new lead compound in hand, we then investigated further refinement of the basic framework by replacement of the imidazo[1,2-a]pyridine moiety and discovered several bioisosteric heterocycles. Extensive optimization of these new heteroaromatic derivatives revealed the detailed structure-activity relationships (SAR) around the imidazo[1, 2-a]pyridine ring and the 2,6-dichlorobenzyl moiety, leading to the discovery of our second clinical candidate 87b (FR173657) which inhibited the specific binding of [3H]BK to recombinant human B2 receptors expressed in Chinese hamster ovary (CHO) cells and guinea pig ileum membrane preparations expressing B2 receptors with IC50's of 1.4 and 0.46 nM, respectively. This compound also displayed excellent in vivo functional antagonistic activity against BK-induced bronchoconstriction in guinea pigs with an ED50 value of 0.075 mg/kg by oral administration. Further modifications of the terminal substituents on the pyridine moiety led to a novel pharmacophore and resulted in the identification of 99 (FR184280), whose IC50 value for human B2 receptors (0.51 nM) was comparable to that of the second-generation peptide B2 antagonist Icatibant.

Effect of spikelets of Miscanthus sinensis on IgE-mediated biphasic cutaneous reaction in mice.

The effect of spikelets of Miscanthus sinensis Andersson (M. sinensis) on IgE-mediated biphasic cutaneous reactions was investigated in BALB/c mice. Mice were passively sensitized by an intravenous (i.v.) injection of monoclonal antidinitrophenol IgE antibody (anti-DNP IgE mAb), or actively by an intraperitoneal (i.p.) injection of DNP-derivatized ovalbumin (DNP-OVA) plus aluminium hydroxide gel (Alum) as an adjuvant. Skin reactions were elicited by an epicutaneous challenge of dinitrofluorobenzene (DNFB) and occurred biphasically with peak responses at 1 and 24 h in both animal models. The administrations of a nondialysable water extract of M. sinensis within 2 h before or after DNFB challenge via oral or i.p. route significantly inhibited the biphasic cutaneous reactions in passively and actively sensitized mice. The inhibitory effect was much stronger than those of a glucocorticoid, prednisolone, and histamine release inhibitor, amlexanox, as positive controls. The active component(s) was predominantly located in the glycoprotein fraction by gel chromatography. In the ears of DNFB-challenged mice, this fraction suppressed the accumulation of inflammatory cells, including mast cells and neutrophils/macrophages. In addition, the biphasic ear swelling was also improved by an administration of the glycoprotein fraction 24 h before active sensitization. These findings indicate that the glycoprotein fraction of M. sinensis was able to inhibit not only the IgE-mediated allergic inflammatory reaction but also the IgE formation. Thus, this fraction may be a useful antiallergic therapy.

[Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer].

To evaluate the efficacy of adjuvant immunochemotherapy, especially the long-term administration of HCFU to patients with noncuratively resected and unresected gastric cancer, a randomized controlled study was conducted by 16 institutions in Hokkaido. After surgery, 185 patients were divided into two groups using the envelope method; group A (84 patients) treated by MMC (4 mg, twice a week, total 1 mg/kg)+OK-432 (or PSK): group B (101 patients) treated with MMC+OK-432+HCFU (600 mg, per day). The 5- and 10-year survival rates were 9.8 and 3.1% in group A, and 11.1 and 11.1% in group B (p=0.062). Better survival rates were obtained in those cases with unresected, S3, or peritoneal dissemination in group B. These results suggested the long-term administration of HCFU was effective for noncuratively resected and unresected gastric cancer.

Assessment of anti-tumor cell effect of human leukocyte interferon in combination with anticancer agents by a convenient assay system in monolayer cell culture.

Cell growth inhibition by anticancer agents was determined by a simple dye-uptake method. This technique could be performed more easily and rapidly than the cell counting method, the method for measurement of 3H-thymidine incorporation, or other dye-uptake methods. The number of viable cells was linearly correlated with the amount of dye taken by the surviving cells, so that the method described in this article could be applied to the assessment of anti-tumor cell effects of human leukocyte interferon (Hu IFN-alpha) in combination with anticancer agents. In combinations of Hu IFN-alpha with anticancer agents such as bleomycin, mitomycin C, and cytosine arabinoside in certain concentration ranges, antagonism was noticed when Hu IFN-alpha and anticancer agents were added simultaneously to the cell culture. However, outside those ranges of concentration, additive effects were observed. Furthermore, the treatment of the cell with IFN followed by the anticancer agents and vice versa showed additive effects.

Effects of interferon on C1300 mouse neuroblastoma.

The effects of murine interferon (MuIFN) with and without cyclophosphamide (CY) were evaluated in C1300 neuroblastoma-bearing mice. Mean survival times were prolonged by administration of 25,000 IU of MuIFN three times per week by ip injection. The combination of MuIFN and CY was more effective in the treatment of mouse neuroblastoma than either agent alone. Our results suggested that MuIFN is synergistic in combination with moderate amounts of CY in mouse neuroblastoma cells and may be given for the treatment of neuroblastoma.